Table 5.
Genitourinary and gastrointestinal toxicity of LDR brachytherapy (JPOPS study)
| Number of patients | Eligible | Scale of adverse event | GU toxicity | GI toxicity | |
|---|---|---|---|---|---|
| Ohashi et al29 JPOPS study (2015) |
2339 | Low-, intermediate-, high-risk | NCI-CTCAE ver. 3.0 | Acute (Grade 2+): 7.4% Late (Grade 2+): 5.8% |
Acute (Grade 2+): 1.0% Late (Grade 2+): 1.9% |
| Katayama et al32 JPOPS study (2016) |
2339 | Low-, intermediate-, high-risk | NCI-CTCAE ver. 3.0 | Not evaluated | LDR alone Acute (Grade 2+): 0.84% Late (Grade 2+): 0.90% LDR + EBRT Acute (Grade 2+): 1.65% Late (Grade 2+): 5.01% |
| Tanaka et al30 JPOPS study (2019) |
2339 | Low-, intermediate-, high-risk | NCI-CTCAE ver. 3.0 | Acute urinary retention All patients (G 2+): 2.3% LDR alone Acute (Grade 3+): 1.1% Late (Grade 3+): 1.1% LDR + EBRT Acute (Grade 3+): 1.3% Late (Grade 3+): 0.8% |
Not evaluated |
EBRT, external beam radiation therapy; GI, gastrointestinal; GU, genitourinary; LDR, low-dose-rate brachytherapy; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events.